| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Tubulin, colchicine binding site. [1]
|
|---|---|
| ln Vitro |
Tubulin inhibitor 11 (Compound 48) (0.03-0.1 μM; 12 hours), stops the cell cycle at the G2/M phase. In cells, tubulin inhibitor 11 phosphorylates histone H3 at Ser10 while increasing cyclin B1 and decreasing cdc2 phosphorylation[1]. Compound 48 (0.03-0.3 μM; 48 hours) induces apoptosis in cancer cells [1]. With an IC50 of 8 nM, tubulin inhibitor 11 (Compound 48) has good antiproliferative effects in DU145 cells[1]. 48; 0.03-0.3 μM) dramatically and dose-dependently lowers the expression levels of α-tubulin and acetyl-α-tubulin[1]. 11 tubulin inhibitors
|
| ln Vivo |
Tubulin inhibitor 11 (Compound 48; po; once daily; 5–10 mg/kg) exhibits strong anticancer efficacies in vivo[1].
|
| Enzyme Assay |
General protocols are described but not specifically performed for Tubulin inhibitor 11:
[3H]-colchicine competitive radioligand binding assay: A standard assay was used to determine percent inhibition of colchicine binding. The method involves incubating test compounds with tubulin and [3H]-colchicine, followed by measurement of bound radioactivity. Percent inhibition is calculated. (Note: Table S1 shows results for compounds 48 and S-40 only; no data for Compound 11). [1] Tubulin polymerization assay: The effect on tubulin polymerization was assessed by measuring absorbance at 340 nm every 30 seconds using a microplate reader. Test compounds (e.g., 10 μM) were used. (No data for Compound 11). [1] |
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: DU145 cells Tested Concentrations: 0.01 μM, 0.03 μM, and 0.1 μM Incubation Duration: 12 hrs (hours) Experimental Results: Caused cell cycle arrest at G2/M phase. Apoptosis Analysis[1] Cell Types: DU145 cells Tested Concentrations: 0.03 μM, 0.1 μM, and 0.3 μM Incubation Duration: 48 hrs (hours) Experimental Results: Induced cancer cell apoptosis. Western Blot Analysis[1] Cell Types: DU145 cells Tested Concentrations: 0.01 μM, 0.03 μM, and 0.1 μM Incubation Duration: 12 hrs (hours) Experimental Results: decreased cdc2 phosphorylation and increased cyclin B1 and phosphorylation of histone H3 at Ser10 in cells. General protocol described but not specifically for Tubulin inhibitor 11: Realtime cytotoxicity assay: Cells (e.g., DU145) were seeded in 16-well E-plates at a density of 5,000 cells per well and treated with indicated concentrations of test compound. Cell viability was monitored in real-time. (No data for Compound 11). [1] |
| Animal Protocol |
Animal/Disease Models: Male athymic BALB/c nude mice (18-20 g) injected with DU145, NCI-H1299 or A549R cells[1]
Doses: 5 mg/kg, 10 mg/kg Route of Administration: po; one time/day Experimental Results: Effectively suppressed tumor growth. General protocols described but not specifically for Tubulin inhibitor 11: Single-dose toxicity study: ICR mice (18-20 g) were orally administered different doses of test compounds. Body weight, health, mortality, and clinical signs were monitored for 14 days. On day 14, animals were euthanized and subjected to gross necropsy. [1] Repeated-dose toxicity study: Kunming mice (18-20 g) were orally administered 10 mg/kg of test compound once daily for 7 days. Body weight was monitored. At the end, liver, kidney, and colon were isolated for H&E staining. (Note: Figure S4 shows data for compound 48 only). [1] |
| References | |
| Additional Infomation |
The Supporting Information provides chemical characterization for Tubulin inhibitor 11:
- ¹H NMR and ¹³C NMR spectra are provided (pages S36-S37). - LC-MS purity: 99.0619% (peak area at retention time 3.782 min) with minor impurities (0.9381% at 4.029 min) as shown on page S37. [1] |
| Molecular Formula |
C22H23N3O3S
|
|---|---|
| Molecular Weight |
409.50132393837
|
| Exact Mass |
409.146
|
| CAS # |
2366260-33-3
|
| PubChem CID |
139369407
|
| Appearance |
Off-white to pink solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
640
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NCC1=CC=C(C)N=C1)(=O)C1=CC=C(C)C(NS(C2=CC=C(C)C=C2)(=O)=O)=C1
|
| InChi Key |
ZKRBQBKMMRYJKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H23N3O3S/c1-15-4-10-20(11-5-15)29(27,28)25-21-12-19(9-6-16(21)2)22(26)24-14-18-8-7-17(3)23-13-18/h4-13,25H,14H2,1-3H3,(H,24,26)
|
| Chemical Name |
4-methyl-3-[(4-methylphenyl)sulfonylamino]-N-[(6-methylpyridin-3-yl)methyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (244.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4420 mL | 12.2100 mL | 24.4200 mL | |
| 5 mM | 0.4884 mL | 2.4420 mL | 4.8840 mL | |
| 10 mM | 0.2442 mL | 1.2210 mL | 2.4420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
